基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 B7-H4抗体 B7H4抗体
  • B7H4抗体—艾普蒂
  • B7H4抗体—艾普蒂
  • B7H4抗体—艾普蒂

1/3

B7H4抗体—艾普蒂

Mouse Monoclonal B7H4 Antibody
询价 20μl 起订
50μl 起订
100μl 起订
上海 更新日期：2025-05-15

上海切尔齐生物科技有限公司

VIP1年
联系人：周经理
电话：027-19371278702拨打
手机：18008634902 拨打
邮箱：ruihening88@163.com

产品详情:

中文名称：
B7H4抗体
英文名称：
Mouse Monoclonal B7H4 Antibody
品牌：
艾普蒂
产地：
武汉
保存条件：
Stored at -20°C for 1158 year. Avoid repeated freeze / thaw cycles.
产品类别：
抗体
重组：
否
应用：
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性：
Human,Mouse,Rat
宿主：
Mouse
偶联物：
无
靶点：
B7H4

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC咨询技术 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesVTCN1; B7X; B7S1; B7-H4; B7h.5; VCTN1; PRO1291
Entrez GeneID79679
clone3A9C12
WB Predicted band size30.9kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human B7H4 (AA: extra 25-259) expressed in HEK293 cells.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Flow cytometric analysis of HL-60 cells using B7H4 mouse mAb (green) and negative control (red).    


           

参考文献

以下是关于B7H4抗体的示例参考文献(虚构示例，仅作格式参考)：

1. **文献名称**: "B7H4 blockade enhances antitumor immunity by potentiating T-cell activation"

**作者**: Smith A, et al.

**摘要**: 研究证明，抗B7H4单克隆抗体可通过阻断B7H4与抑制性受体(如未知配体)的相互作用，逆转肿瘤微环境中的T细胞耗竭，在卵巢癌和乳腺癌小鼠模型中显著抑制肿瘤生长。

2. **文献名称**: "Development of a B7H4-targeting antibody-drug conjugate for solid tumors"

**作者**: Lee C, et al.

**摘要**: 该研究开发了一种新型B7H4抗体-药物偶联物(ADC)，通过将细胞毒性药物与抗B7H4抗体结合，在胰腺癌和肺癌的临床前模型中显示出特异性肿瘤杀伤作用，且对正常组织毒性较低。

3. **文献名称**: "B7H4 expression correlates with immune evasion and poor prognosis in hepatocellular carcinoma"

**作者**: Zhang Y, et al.

**摘要**: 通过分析肝癌患者样本，发现B7H4的高表达与CD8+ T细胞浸润减少及患者生存期缩短相关。体外实验表明，抗B7H4抗体可恢复T细胞对肿瘤细胞的杀伤能力。

4. **文献名称**: "Combination therapy of anti-B7H4 and PD-1 antibodies synergizes antitumor efficacy"

**作者**: Wang H, et al.

**摘要**: 研究显示，抗B7H4抗体与抗PD-1联用可协同增强抗肿瘤免疫应答，在黑色素瘤模型中显著提高治疗效果，提示B7H4是联合免疫治疗的潜在靶点。

**注意**：以上文献为示例，实际文献需通过PubMed、Web of Science等数据库检索。真实研究中可关注关键词如"B7H4 antibody"、"VTCN1"(B7H4基因名)及"immune checkpoint"。

       

背景信息

B7H4 (B7 homolog 4), also known as VTCN1. is a transmembrane protein belonging to the B7 immune checkpoint family. It plays a critical role in modulating T-cell-mediated immune responses, primarily by suppressing T-cell activation and cytokine production. Unlike other immune checkpoints like PD-1/PD-L1. B7H4 is minimally expressed in normal tissues but is frequently overexpressed in various cancers, including breast, ovarian, pancreatic, and lung cancers. This tumor-selective expression pattern makes it an attractive therapeutic target to limit off-target toxicity.

B7H4 antibodies are designed to block its immunosuppressive function, thereby restoring antitumor immunity. Preclinical studies show that anti-B7H4 monoclonal antibodies or antibody-drug conjugates (ADCs) can inhibit tumor growth and enhance T-cell infiltration. Additionally, B7H4’s role in immune evasion and its association with poor prognosis in cancer patients have spurred clinical interest. Several anti-B7H4 agents, including ADCs like AZD8205 and HuB7H4-ADC, are under evaluation in early-phase trials.

Challenges remain in understanding B7H4’s ligand interactions and regulatory mechanisms. However, its potential synergy with existing immunotherapies positions B7H4 as a promising target for next-generation cancer treatments.

       
B7H4抗体;B7H4;B7H4 Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业，

成立日期 (2年)
注册资本 20万人民币
员工人数 1-10人
年营业额 ￥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 抗体,蛋白组学,细胞生物学

B7H4抗体相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价